• +1-646-491-9876
    • +91-20-67278686

    Search

    Hypotension - Pipeline Review, H1 2017

    Hypotension - Pipeline Review, H1 2017

    • Report Code ID: RW0001689452
    • Category Healthcare
    • No. of Pages 43
    • Publication Month Mar-17
    • Publisher Name Global Markets Direct
    Report Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Hypotension - Pipeline Review, H1 2017, provides an overview of the Hypotension (Cardiovascular) pipeline landscape.

    Low blood pressure, or hypotension, occurs when blood pressure during and after each heartbeat is much lower than usual. This means the heart, brain, and other parts of the body do not get enough blood. Symptoms include blurred vision, dizziness, confusion, sleeplessness and weakness. Treatment is required for patients with signs and symptoms.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Hypotension - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hypotension (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Hypotension (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Hypotension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Phase I stages are 2, 3 and 1 respectively.

    Hypotension (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Report Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Hypotension (Cardiovascular).
    - The pipeline guide reviews pipeline therapeutics for Hypotension (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Hypotension (Cardiovascular) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Hypotension (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Hypotension (Cardiovascular)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Hypotension (Cardiovascular).
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Hypotension (Cardiovascular) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Hypotension - Overview
    Hypotension - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Products under Development by Companies
    Hypotension - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Hypotension - Companies Involved in Therapeutics Development
    Anexon Inc
    BCO Pharma Ltd
    La Jolla Pharmaceutical Company
    Theravance Biopharma Inc
    TrioxBio Inc
    Hypotension - Drug Profiles
    angiotensin II acetate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ANX-042 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    dopamine hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MTR-105 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MTR-107 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TD-9855 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Hypotension - Dormant Projects
    Hypotension - Product Development Milestones
    Featured News & Press Releases
    Feb 27, 2017: La Jolla Pharmaceutical Company Announces Positive Top-Line Results from ATHOS-3 Phase 3 Study of LJPC-501
    Nov 30, 2015: La Jolla Pharmaceutical Company Announces Notice of Allowance for U.S. Patent Covering LJPC-501
    Feb 09, 2015: La Jolla Pharmaceutical Company Announces Special Protocol Assessment for Planned Phase 3 Trial of LJPC-501 in Catecholamine-Resistant Hypotension
    Jul 08, 2014: La Jolla Pharmaceutical Company Announces Planned Initiation of Phase 3 Registration Program for LJPC-501 in Resistant Hypotension
    Nov 19, 2008: Chelsea Therapeutics Completes Enrollment In Phase II Trial Of Droxidopa In Intradialytic Hypotension
    Nov 19, 2008: Chelsea Therapeutics Completes Enrollment In Phase II Trial Of Droxidopa In Intradialytic Hypotension
    Nov 03, 2008: Chelsea Therapeutics Reports Significant Reduction In Severity Of Symptoms During Titration Phase Of Pivotal Droxidopa Study In Neurogenic Orthostatic Hypotension
    Oct 29, 2008: Data From Chelsea Therapeutics Phase III Trial Of Droxidopa in Neurogenic Orthostatic Hypotension To Be Presented At 19th Annual International Symposium On The Autonomic Nervous System
    Sep 02, 2008: Chelsea Therapeutics Begins Patient Dosing In Second Pivotal Phase III Trial Of Droxidopa In Neurogenic Orthostatic Hypotension
    Aug 26, 2008: Chelsea Therapeutics Receives Fast Track Designation For Droxidopa For Symptomatic Neurogenic Orthostatic Hypotension
    Feb 07, 2008: Chelsea Therapeutics Begins Patient Dosing In Pivotal Phase III Trial Of Droxidopa In Neurogenic Orthostatic Hypotension
    Nov 12, 2007: FDA Accepts Chelsea Therapeutics Investigational New Drug Application For Droxidopa
    Aug 14, 2007: European Commission Grants Chelsea Therapeutics Two Orphan Medicinal Product Designations For Droxidopa
    Jan 22, 2007: FDA Grants Chelsea Therapeutics Orphan Drug Designation For Droxidopa
    Jan 11, 2007: Chelsea Therapeutics Announces Results Of European Phase IIb Trial Of Droxidopa
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Hypotension, H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Hypotension - Pipeline by Anexon Inc, H1 2017
    Hypotension - Pipeline by BCO Pharma Ltd, H1 2017
    Hypotension - Pipeline by La Jolla Pharmaceutical Company, H1 2017
    Hypotension - Pipeline by Theravance Biopharma Inc, H1 2017
    Hypotension - Pipeline by TrioxBio Inc, H1 2017
    Hypotension - Dormant Projects, H1 2017

    List of Figures

    Number of Products under Development for Hypotension, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Anexon Inc
    BCO Pharma Ltd
    La Jolla Pharmaceutical Company
    Theravance Biopharma Inc
    TrioxBio Inc

    Request for Sample

    Report Url http://www.reportsweb.com//hypotension-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//hypotension-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//hypotension-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments